Latest IR Information
Financial Highlights | 1st Quarter of Fiscal 2026
First quarter of the fiscal year ending March 31, 2027 (April 1, 2026 to June 30, 2026) | Announced August 3, 2026
For the first quarter of fiscal 2026, consolidated revenue was 163.3 billion yen (up 63.7% year on year), operating profit was 66.9 billion yen (up
90.6%) and profit attributable to owners of parent was 97.7 billion yen (up 148.2%). Revenue growth was driven mainly by the consolidation of Torii
Pharmaceutical, the succession to the edaravone business (RADICUT / RADICAVA) and an increase in royalty income centered on the HIV franchise.
Revenue, operating profit and profit attributable to owners of parent all reached record highs for a first quarter. We are making steady progress
toward achieving the full-year forecast for FY2026.
| Revenue | Operating profit | Profit attributable to owners of parent | |
| Results | 163.3 B yen | 66.9 B yen | 97.7 B yen |
| Y o Y | +63.7% | +90.6% | +148.2% |